After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Novavax (NVAX) closed the most recent trading day at $8.45, moving +0.24% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Novavax Inc. closed 63.58% short of its 52-week high of $23.86, which the company reached on June 6th.

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.

We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and ...

Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.

to which Novavax belongs, has lost 6% over this period. Now the key question is: Where could the stock be headed in the near term? While media releases or rumors about a substantial change in a ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference ... including its nucleus, wherein it releases its genetic material. The machinery of this cell ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...